Ertapenem Dosage
Medically reviewed by Drugs.com. Last updated on Jun 29, 2021.
Applies to the following strengths: 1 g
Usual Adult Dose for:
- Intraabdominal Infection
- Pelvic Infections
- Pneumonia
- Pyelonephritis
- Urinary Tract Infection
- Skin or Soft Tissue Infection
- Infection Prophylaxis
Usual Pediatric Dose for:
- Intraabdominal Infection
- Pelvic Infections
- Pneumonia
- Pyelonephritis
- Urinary Tract Infection
- Skin or Soft Tissue Infection
Additional dosage information:
Usual Adult Dose for Intraabdominal Infection
1 g IV or IM once a day for 5 to 14 days
Use: For the treatment of complicated intraabdominal infections due to Escherichia coli, Clostridium clostridioforme, Eggerthella lenta (previously Eubacterium lentum), Peptostreptococcus species, Bacteroides fragilis, B distasonis, B ovatus, B thetaiotaomicron, or B uniformis
Usual Adult Dose for Pelvic Infections
1 g IV or IM once a day for 3 to 10 days
Use: For the treatment of acute pelvic infections (including postpartum endomyometritis, septic abortion, postsurgical gynecological infections) due to Streptococcus agalactiae, E coli, B fragilis, Porphyromonas asaccharolytica, Peptostreptococcus species, or Prevotella bivia
Usual Adult Dose for Pneumonia
1 g IV or IM once a day
Total duration of therapy: 10 to 14 days
Comments:
-Duration includes a possible conversion to appropriate oral therapy (after at least 3 days of parenteral therapy) once clinical improvement established.
Uses:
-For the treatment of community-acquired pneumonia due to S pneumoniae (penicillin-susceptible isolates only) including cases with concomitant bacteremia, Haemophilus influenzae (beta-lactamase negative isolates only), or Moraxella catarrhalis
-For the treatment of complicated urinary tract infections (including pyelonephritis) due to E coli, including cases with concomitant bacteremia, or Klebsiella pneumoniae
Usual Adult Dose for Pyelonephritis
1 g IV or IM once a day
Total duration of therapy: 10 to 14 days
Comments:
-Duration includes a possible conversion to appropriate oral therapy (after at least 3 days of parenteral therapy) once clinical improvement established.
Uses:
-For the treatment of community-acquired pneumonia due to S pneumoniae (penicillin-susceptible isolates only) including cases with concomitant bacteremia, Haemophilus influenzae (beta-lactamase negative isolates only), or Moraxella catarrhalis
-For the treatment of complicated urinary tract infections (including pyelonephritis) due to E coli, including cases with concomitant bacteremia, or Klebsiella pneumoniae
Usual Adult Dose for Urinary Tract Infection
1 g IV or IM once a day
Total duration of therapy: 10 to 14 days
Comments:
-Duration includes a possible conversion to appropriate oral therapy (after at least 3 days of parenteral therapy) once clinical improvement established.
Uses:
-For the treatment of community-acquired pneumonia due to S pneumoniae (penicillin-susceptible isolates only) including cases with concomitant bacteremia, Haemophilus influenzae (beta-lactamase negative isolates only), or Moraxella catarrhalis
-For the treatment of complicated urinary tract infections (including pyelonephritis) due to E coli, including cases with concomitant bacteremia, or Klebsiella pneumoniae
Usual Adult Dose for Skin or Soft Tissue Infection
1 g IV or IM once a day for 7 to 14 days
Comments:
-Not studied in diabetic foot infections with concurrent osteomyelitis
-Patients with diabetic foot infections received up to 28 days of treatment (parenteral or parenteral plus oral conversion therapy).
Use: For the treatment of complicated skin and skin structure infections (including diabetic foot infections without osteomyelitis) due to Staphylococcus aureus (methicillin-susceptible isolates only), S agalactiae, S pyogenes, E coli, K pneumoniae, Proteus mirabilis, B fragilis, Peptostreptococcus species, P asaccharolytica, or P bivia
Usual Adult Dose for Infection Prophylaxis
1 g IV once as a single dose, 1 hour before surgical incision
Use: For the prevention of surgical site infection after elective colorectal surgery
Usual Pediatric Dose for Intraabdominal Infection
3 months to 12 years: 15 mg/kg IV or IM twice a day
-Maximum dose: 1 g/day
13 years or older: 1 g IV or IM once a day
Duration of therapy: 5 to 14 days
Use: For the treatment of complicated intraabdominal infections due to E coli, C clostridioforme, E lenta (previously E lentum), Peptostreptococcus species, B fragilis, B distasonis, B ovatus, B thetaiotaomicron, or B uniformis
Usual Pediatric Dose for Pelvic Infections
3 months to 12 years: 15 mg/kg IV or IM twice a day
-Maximum dose: 1 g/day
13 years or older: 1 g IV or IM once a day
Duration of therapy: 3 to 10 days
Use: For the treatment of acute pelvic infections (including postpartum endomyometritis, septic abortion, postsurgical gynecological infections) due to S agalactiae, E coli, B fragilis, P asaccharolytica, Peptostreptococcus species, or P bivia
Usual Pediatric Dose for Pneumonia
3 months to 12 years: 15 mg/kg IV or IM twice a day
-Maximum dose: 1 g/day
13 years or older: 1 g IV or IM once a day
Total duration of therapy: 10 to 14 days
Comments:
-Duration includes a possible conversion to appropriate oral therapy (after at least 3 days of parenteral therapy) once clinical improvement established.
Uses:
-For the treatment of community-acquired pneumonia due to S pneumoniae (penicillin-susceptible isolates only) including cases with concomitant bacteremia, H influenzae (beta-lactamase negative isolates only), or M catarrhalis
-For the treatment of complicated urinary tract infections (including pyelonephritis) due to E coli, including cases with concomitant bacteremia, or K pneumoniae
Usual Pediatric Dose for Pyelonephritis
3 months to 12 years: 15 mg/kg IV or IM twice a day
-Maximum dose: 1 g/day
13 years or older: 1 g IV or IM once a day
Total duration of therapy: 10 to 14 days
Comments:
-Duration includes a possible conversion to appropriate oral therapy (after at least 3 days of parenteral therapy) once clinical improvement established.
Uses:
-For the treatment of community-acquired pneumonia due to S pneumoniae (penicillin-susceptible isolates only) including cases with concomitant bacteremia, H influenzae (beta-lactamase negative isolates only), or M catarrhalis
-For the treatment of complicated urinary tract infections (including pyelonephritis) due to E coli, including cases with concomitant bacteremia, or K pneumoniae
Usual Pediatric Dose for Urinary Tract Infection
3 months to 12 years: 15 mg/kg IV or IM twice a day
-Maximum dose: 1 g/day
13 years or older: 1 g IV or IM once a day
Total duration of therapy: 10 to 14 days
Comments:
-Duration includes a possible conversion to appropriate oral therapy (after at least 3 days of parenteral therapy) once clinical improvement established.
Uses:
-For the treatment of community-acquired pneumonia due to S pneumoniae (penicillin-susceptible isolates only) including cases with concomitant bacteremia, H influenzae (beta-lactamase negative isolates only), or M catarrhalis
-For the treatment of complicated urinary tract infections (including pyelonephritis) due to E coli, including cases with concomitant bacteremia, or K pneumoniae
Usual Pediatric Dose for Skin or Soft Tissue Infection
3 months to 12 years: 15 mg/kg IV or IM twice a day
-Maximum dose: 1 g/day
13 years or older: 1 g IV or IM once a day
Duration of therapy: 7 to 14 days
Comments:
-Not studied in diabetic foot infections with concurrent osteomyelitis
-Adult patients with diabetic foot infections received up to 28 days of treatment (parenteral or parenteral plus oral conversion therapy).
Use: For the treatment of complicated skin and skin structure infections (including diabetic foot infections without osteomyelitis) due to S aureus (methicillin-susceptible isolates only), S agalactiae, S pyogenes, E coli, K pneumoniae, P mirabilis, B fragilis, Peptostreptococcus species, P asaccharolytica, or P bivia
Renal Dose Adjustments
Adult patients:
-CrCl greater than 30 mL/min/1.73 m2: No adjustment recommended.
-Severe renal dysfunction (CrCl up to 30 mL/min/1.73 m2) and ESRD (CrCl up to 10 mL/min/1.73 m2): 500 mg IV or IM once a day
Pediatric patients:
-Renal dysfunction: Data not available
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
-Known hypersensitivity to the active component, any of the ingredients, or other drugs in the same class
-Demonstrated anaphylactic reactions to beta-lactams
-IM: Known hypersensitivity to amide-type local anesthetics
Safety and efficacy have not been established in patients younger than 3 months; this drug is not recommended for use in these patients.
Consult WARNINGS section for additional precautions.
Dialysis
Adult patients:
-Hemodialysis: 500 mg IV or IM once a day
---If administered at least 6 hours before hemodialysis: No supplemental dose is needed.
---If administered within 6 hours before hemodialysis: A supplemental dose of 150 mg is recommended after the hemodialysis session.
-Peritoneal dialysis or hemofiltration: Data not available
Pediatric patients: Data not available
Other Comments
Administration advice:
-For IV or IM use
-IV: Infuse over 30 minutes; do not use with a needleless IV system.
-IV: Complete the infusion within 6 hours of reconstitution.
-IM: May use as an alternative to IV administration for infections where IM therapy is appropriate; administer by deep IM injection into a large muscle mass (e.g., gluteal muscles, lateral part of the thigh); use caution to avoid inadvertent injection into a blood vessel.
-IM: Use the IM solution within 1 hour after reconstitution.
-May administer by IV infusion for up to 14 days or by IM injection for up to 7 days
-Do not administer the reconstituted solution IV.
-Do not co-infuse with other drugs.
Storage requirements:
-Before reconstitution: Do not store above 25C (77F).
-Reconstituted and infusion solutions: Reconstituted solution (immediately diluted) may be stored at room temperature (25C) and used within 6 hours or stored for 24 hours refrigerated and used within 4 hours after removal from refrigerator; do not freeze solutions.
Reconstitution/preparation techniques:
-This drug must be reconstituted and then diluted before IV administration.
-This drug must be reconstituted with lidocaine (without epinephrine) before IM administration.
-Diluents containing dextrose (alfa-D-Glucose) should not be used.
-The manufacturer product information should be consulted.
IV compatibility:
-Compatible: Water for Injection, 0.9% Sodium Chloride Injection, Bacteriostatic Water for Injection
-Do not mix with other drugs.
General:
-This drug is for the specified moderate to severe infections due to susceptible isolates of the designated microorganisms.
-To reduce the development of drug-resistant organisms and maintain effective therapy, antibiotics should be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria.
-Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.
Monitoring:
-General: Organ system functions, including renal, hepatic, and hematopoietic (periodically during prolonged therapy)
-Hematologic: Hematopoietic function (periodically during prolonged therapy)
-Hepatic: Hepatic function (periodically during prolonged therapy)
-Renal: Renal function (periodically during prolonged therapy)
Patient advice:
-Avoid missing doses and complete the entire course of therapy.
-Contact physician as soon as possible if watery and bloody stools (with or without stomach cramps and fever) develop.
More about ertapenem
- Side effects
- Drug interactions
- During pregnancy or Breastfeeding
- Reviews (3)
- Pricing & coupons
- En español
- Drug class: carbapenems
Patient resources
- Other brands
- Invanz
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.